SB AlertDue to the anticipated winter storm, all classes and in-person events for Monday, Jan. 26 are canceled across Stony Brook Main Campus, Southampton, and Manhattan. Go to Office of Emergency Management for more information.   More information
Skip Navigation
Search
HomeEvents Brook And Beyond CohortsBrook & Beyond Cohort: Extended-Release Steroid Injection

Extended-Release Steroid Injection for Thumb Arthritis

About

Thumb (CMC joint) arthritis is often treated with braces, NSAIDs, or standard steroid injections, which give only short-term relief and can lead to surgery. We propose testing an extended-release triamcinolone injection (TA-ER), already FDA-approved for knee osteoarthritis, as a longer-lasting, non-surgical option for thumb arthritis. In a randomized, placebo-controlled trial, we aim to show that TA-ER reduces pain and improves hand function, building on promising Phase 1 and 2 results.

Team

Dr. Marie Badalamente (PI)
Dr. Samantha Muhlrad (CO-PI)
Susan Greco, Clinical Studies Coordinator

Why It Matters

  • 6–7% of adults over 50 have painful thumb arthritis
  • By age 70: 1 in 4 men, 1 in 3 women affected
  • Millions of patients need reliable, non-surgical pain relief

How Might We

How might we provide longer-lasting, non-surgical pain relief and improved function for patients with thumb arthritis?

Elevator Pitch

An extended-release steroid injection (TA-ER) offers 12 weeks of relief for thumb arthritis — a longer-lasting, non-surgical solution.

Stage: Catalyze/Scale

Preparing for Phase 3 / Expanded Clinical Trials

How B&B Can Help

Beyond funding, our biggest need:
● Additional clinical test sites to expand patient recruitment for upcoming trials